Lasho et al. described a case of WHO-defined CNL with concurrent CSF3RT618I and SETBP1 mutations failing treatment with Hydroxyurea subsequently treated with Ruxolitinib 10 mg orally daily in addition to Hydroxyurea133. This evidence concerns the gene SETBP1 and chronic neutrophilic leukemia.